SCHEMBL651114

SCHEMBL651114

Cc1cc(O)ccc1/N=C1/NC(=O)/C(=C/c2cnc(NC(=O)CN3CCN(C)CC3)s2)S1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.41
NPSR1 Q6W5P4 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
MAPK1 P28482 1/20 0.41
LMNA P02545 3/20 0.40
RECQL P46063 1/20 0.40
HPGD P15428 2/20 0.40
POLB P06746 1/20 0.40
RNASEL Q05823 1/20 0.40
ALOX15 P16050 2/20 0.38
CDC25B P30305 2/20 0.38
PTPN1 P18031 1/20 0.38
GSK3B P49841 2/20 0.38
DYRK1A Q13627 2/20 0.38
WNT1 P04628 1/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
HBB P68871 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650766 1.00 MAPT (0.41) MAPTNPSR1TDP1L3MBTL1MAPK1
SCHEMBL650022 0.86 MAPT (0.45) MAPTNPSR1TDP1L3MBTL1MAPK1
SCHEMBL651049 0.86 MKNK1 (0.42) MAPTNPSR1TDP1L3MBTL1MAPK1
SCHEMBL650023 0.86 MAPT (0.45) MAPTNPSR1TDP1L3MBTL1MAPK1
SCHEMBL651383 0.86 RNASEL (0.43) MAPTNPSR1TDP1L3MBTL1MAPK1
SCHEMBL649993 0.86 RNASEL (0.43) MAPTNPSR1TDP1L3MBTL1MAPK1
SCHEMBL649588 0.85 MAPT (0.46) MAPTNPSR1TDP1L3MBTL1MAPK1
SCHEMBL649589 0.85 MAPT (0.46) MAPTNPSR1TDP1L3MBTL1MAPK1
SCHEMBL653416 0.85 MAPT (0.42) MAPTNPSR1TDP1L3MBTL1MAPK1
SCHEMBL652441 0.85 MAPT (0.42) MAPTNPSR1TDP1L3MBTL1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 MAPT 3657/4885NPSR1 4464/4885TDP1 1880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.